NCT00037661
Completed
Phase 3
Double-Masked, Randomized, Placebo-Controlled Study of Efficacy Parameter Following Administration of INS365 Ophthalmic Solution or Placebo in a Controlled Adverse Environment (CAE) Chamber in Subjects With Non-Sjogren's Associated Dry Eye
ConditionsKeratoconjunctivitis Sicca
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Keratoconjunctivitis Sicca
- Sponsor
- Merck Sharp & Dohme LLC
- Enrollment
- 222
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
Comparative efficacy trial of INS365 Ophthalmic Solution and placebo in patients with dry eye.
Investigators
Eligibility Criteria
Inclusion Criteria
- •have Non-Sjogren's associated dry eye disease with symptoms lasting greater than 6 months
- •had intermittent or regular artificial tear use within past 3 months
Exclusion Criteria
- •had LASIK surgery
- •had punctal occlusion or cauterization within last 3 months
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
Study of INS365 Ophthalmic Solution in Subjects With Dry Eye DiseaseDry Eye DiseaseNCT00404131Merck Sharp & Dohme LLC500
Completed
Phase 3
Study of INS365 Ophthalmic Solution in Subjects With Dry Eye DiseaseDry Eye DiseaseNCT00403715Merck Sharp & Dohme LLC500
Completed
Phase 2
Safety and Efficacy of TOP1630 for Dry Eye SyndromeDry Eye SyndromeNCT03088605ORA, Inc.69
Completed
Phase 2
A Study of INS365 Ophthalmic Solution in Patients With Moderate to Severe Dry Eye DiseaseDry Eye DiseaseNCT00679718Merck Sharp & Dohme LLC150
Completed
Phase 2
Study of TOP1630 for Dry Eye SyndromeDry Eye SyndromeNCT03833388Topivert Pharma Ltd202